Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Hyperion Therapeutics, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Hyperion Therapeutics, Inc. (NASDAQ:HPTX).

Most recent broker ratings

03/31/2015 – Hyperion Therapeutics, Inc. had its “hold” rating reiterated by analysts at Needham & Company.

03/31/2015 – Hyperion Therapeutics, Inc. was downgraded to “hold” by analysts at Brean Capital. They now have a USD 51 price target on the stock.

03/31/2015 – Hyperion Therapeutics, Inc. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 46 price target on the stock.

03/30/2015 – Hyperion Therapeutics, Inc. was downgraded to “neutral” by analysts at Wedbush. They now have a USD 52 price target on the stock.

03/30/2015 – Hyperion Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Roth Capital. They now have a USD 46 price target on the stock.

02/27/2015 – Hyperion Therapeutics, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 38 price target on the stock.

02/27/2015 – Hyperion Therapeutics, Inc. was upgraded to “outperform” by analysts at Zacks. They now have a USD 29.7 price target on the stock.

08/08/2014 – Hyperion Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Keefe, Bruyette & Woods. They now have a USD 37 price target on the stock.

02/28/2014 – Hyperion Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 39 price target on the stock.

02/28/2014 – Hyperion Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 40 price target on the stock.

Hyperion Therapeutics, Inc. has a 50 day moving average of 46.00 and a 200 day moving average of 46.00. It has a 52-week low of 46.00 and a 52-week high of 46.00.

The share price of the company (NASDAQ:HPTX) was up +0.00%, with a high of 0.00 during the day and the volume of Hyperion Therapeutics, Inc. shares traded was 0.

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.